Clinical trials
Cardiotoxicity clinical trials
Below are recruiting cardiotoxicity clinical trials, each written for real people, not researchers. We’re tracking 50 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07233499RecruitingPhase 2
Nebivolol for heart protection during breast cancer treatment
This trial tests if the drug nebivolol can protect the heart from damage caused by trastuzumab (Herceptin) in women with HER2-positive breast cancer. If effective, it may help prevent heart problems while still allowing cancer treatment.
CairoAges 18–65 - NCT05406635Recruiting
Imaging vs blood tests to guide heart-safe HER2 treatment
This trial compares whether special heart imaging or blood tests better helps monitor heart safety while you receive HER2-targeted therapy (like trastuzumab, with or without pertuzumab) plus chemotherapy. It may help doctors catch early heart stress and choose the safest treatment plan for you.
AalborgAges 18–90 - NCT07157670Recruiting
Heart health study after stem cell transplant
This study looks at heart problems that can happen after a stem cell transplant from a donor (allogeneic). It aims to understand these risks better so doctors can help patients stay healthier after transplant.
ParisAges 15 years+ - NCT07158450Enrolling by invitation
Heart health check for cancer patients
This trial tests a new device that monitors heart health during cancer treatment. It uses a simple on-body sensor alongside your regular echocardiogram to see if it can detect heart changes early.
Golden, ColoradoAges 18 years+ - NCT07070765Recruiting
Study on dapagliflozin to protect the heart during breast cancer chemo
This trial tests if a heart-protecting drug called dapagliflozin can help prevent heart damage in breast cancer patients receiving a type of chemotherapy called anthracycline. It may be an option if you have low to medium heart risk factors.
Aberdeen, AberdeenshireAges 18–70 - NCT07058454Recruiting
Heart safety study for targeted cancer therapies
This study looks at how targeted cancer treatments affect the heart. If you are an adult with any type of cancer and are getting or will get chemotherapy (including targeted drugs), joining this study helps doctors understand heart risks better.
Guangzhou, GuangdongAges 18 years+ - NCT06930521Recruiting
Monitoring heart health during HER2 therapy for breast cancer
This study tracks how well the heart handles HER2-targeted therapy (like Herceptin) during the first year of treatment for early-stage breast cancer. It helps keep you safe by checking heart function closely.
Toronto, OntarioAges 18–79 - NCT06699056Recruiting
AI heart monitor study for ejection fraction
This study uses an AI-powered wearable monitor to check how well your heart pumps blood (ejection fraction) from a simple EKG recording. It may help doctors quickly assess heart function without extra tests.
Orange, CaliforniaAges 18 years+ - NCT06595147Recruiting
Exercise for heart health in breast cancer survivors
This study tests if a 12-week exercise program improves heart health in women over 60 who have finished treatment for early-stage breast cancer. You will be placed in either an aerobic exercise group or a stretching group to see which helps your heart more.
Edmonton, AlbertaAges 60 years+ - NCT06491680RecruitingPhase 4
Heart safety during breast cancer chemo
This trial checks how well the heart handles anthracycline chemotherapy in breast cancer patients. It helps doctors find early signs of heart side effects so they can keep you safe during treatment.
Cairo, Cairo GovernorateAges 18–60 - NCT06443645Recruiting
Protecting the heart during breast cancer treatment
This trial tests whether a diabetes medicine (SGLT2 inhibitor) can prevent heart damage caused by a common chemotherapy drug (anthracycline) in people with early-stage breast cancer. If you are newly diagnosed and about to start chemotherapy or have surgery, this study may be for you.
StrasbourgAges 18 years+ - NCT06427226RecruitingPhase 2
Testing dapagliflozin to protect the heart during breast cancer chemo
This trial tests whether a daily pill called dapagliflozin can help protect the heart from damage caused by doxorubicin chemotherapy in people being treated for early-stage breast cancer. If you are starting doxorubicin and have a healthy heart, this might lower your risk of heart problems later.
Alexandria, Bab SharqiAges 18–65 - NCT06353191Recruiting
Blood markers to predict heart problems from cancer therapy
This study looks for early warning signs (biomarkers) of heart damage caused by cancer treatments. It is for people who have had cancer treatment, may have heart issues, or are about to start a treatment that could affect the heart.
Scottsdale, ArizonaAges 18 years+ - NCT06310330Recruiting
Heart monitoring study for breast cancer patients
This study uses heart ultrasound (echocardiogram) to find early signs of heart damage from breast cancer treatment. It aims to better protect your heart during and after therapy.
TrondheimAges 18 years+ - NCT06211413Enrolling by invitation
Tracking heart issues in CLL patients on BTK inhibitors
This study watches for high blood pressure and irregular heartbeats in people with CLL who are starting a type of targeted therapy called a BTK inhibitor (acalabrutinib or zanubrutinib). Researchers will use a smartwatch and blood pressure cuff to monitor your heart health at home.
Philadelphia, PennsylvaniaAges 22 years+ - NCT06183437RecruitingPhase 4
Can I stop heart meds after cancer therapy?
This trial tests whether it is safe to stop taking heart failure medications in people who developed heart weakness after cancer treatment but whose heart function has since recovered. It aims to see if stopping these drugs leads to any worsening of heart health.
Los Angeles, CaliforniaAges 18 years+ - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Anchorage, AlaskaAges 18 years+ - NCT06023576RecruitingPhase 2
Blood pressure control during breast cancer chemo
This study tests whether careful blood pressure management can help protect the heart during certain types of chemotherapy (anthracyclines) for breast cancer. Participants will use a smart blood pressure device and may also do an exercise test.
Basking Ridge, New JerseyAges 18 years+ - NCT05921253RecruitingEarly Phase 1
Check a brain-heart device to reduce chemo heart risk
This early-phase study tests a “neuromodulation” device (stimulating nerves that may affect the heart and blood vessels) to help lower cardiovascular risks after certain cancer chemotherapy. It may be most relevant if you recently had an anthracycline-based treatment and also have other heart-risk factors.
Oklahoma City, OklahomaAges 18–99 - NCT05023785Recruiting
Lifestyle program for cancer survivors with early heart strain
This trial tests a structured lifestyle and exercise change program for young people who finished cancer treatment and have signs of early heart weakness. The goal is to improve heart health and lower the chance of heart failure later.
Toronto, OntarioAges 18–45 - NCT05598879Recruiting
New heart-cancer visit registry for adults
This study is a “registry,” meaning it collects health information from adults who are getting a new heart (cardio) evaluation related to cancer. It helps doctors better understand heart risks and care needs for different cancer types and treatments.
Weston, FloridaAges 18 years+ - NCT05256745RecruitingPhase 1/Phase 2
A medicine to protect the heart during breast cancer chemotherapy
This early-phase study tests azeliragon to lower the risk of chemotherapy-related heart damage in women with early-stage breast cancer. Participants get their planned standard chemotherapy, plus the study medicine, and are monitored for safety and heart health.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04260269Enrolling by invitation
Testing a switch to a different chemotherapy type after heart side effects
This study looks at whether people with solid tumors who develop heart-related side effects during a fluoropyrimidine chemotherapy can safely switch to a different fluoropyrimidine. It aims to see if the new option is feasible to use again when the first one caused cardiotoxicity.
OdenseAges 18 years+ - NCT03882580Recruiting
Heart care during cancer treatment
This trial looks at how a special heart clinic can help cancer patients avoid or manage heart problems caused by their cancer treatment. It aims to find the best ways to detect, prevent, and treat heart issues during cancer care.
Paris, FranceAges 18 years+
Hear when a new Cardiotoxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cardiotoxicity?
- Yes. Clin2 currently lists 50 recruiting cardiotoxicity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cardiotoxicity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cardiotoxicity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.